Navigation Links
Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
Date:10/26/2010

BASKING RIDGE, N.J., Oct. 26 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Oppenheimer 21st Annual Healthcare Conference.  Dr. Mazzo's presentation will be given at the Waldorf-Astoria Hotel in New York City on Tuesday, November 2, 2010 at 10:45 a.m. EDT in the Louis XVI Room.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system, REG1.ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007). &
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
2. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
3. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
4. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
5. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
6. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
7. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
8. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
9. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
(Date:11/18/2014)... 18, 2014 Array Architects is proud ... expertise to the nation's hospitals and health systems. It ... those dedicating their careers to the advancement of both ... in her respective field, Laura Silvoy has been chosen ... 2014 Winter Simulation Conference. , Laura will present ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
... Fourth Quarter Highlights:, -- Record revenues of $82.0 million, up 22% from the prior year,s fourth ... quarter ... $0.23, a 130% increase over last year,s ... of $24.3 million, revolving debt facility paid off, -- Launch of four new food and beverage products and ...
... WILMINGTON, N.C., Dec. 12 PPD, Inc. ... M.D., as director,of strategic development, to lead the ... Dr. Mathew will provide strategic leadership for PPD,s ... project management,and patient recruitment for key therapeutic areas. ...
... 12 Beckman Coulter,Inc. (NYSE: BEC ), ... complex biomedical testing, announced today that Susan R.,Nowakowski, ... Services, Inc. (NYSE: AHS ) has been ... effective December 10., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2007 Financial Results 2Martek Announces Fourth Quarter and FY 2007 Financial Results 3Martek Announces Fourth Quarter and FY 2007 Financial Results 4Martek Announces Fourth Quarter and FY 2007 Financial Results 5Martek Announces Fourth Quarter and FY 2007 Financial Results 6Martek Announces Fourth Quarter and FY 2007 Financial Results 7Martek Announces Fourth Quarter and FY 2007 Financial Results 8Martek Announces Fourth Quarter and FY 2007 Financial Results 9Martek Announces Fourth Quarter and FY 2007 Financial Results 10Martek Announces Fourth Quarter and FY 2007 Financial Results 11Martek Announces Fourth Quarter and FY 2007 Financial Results 12Martek Announces Fourth Quarter and FY 2007 Financial Results 13Martek Announces Fourth Quarter and FY 2007 Financial Results 14Martek Announces Fourth Quarter and FY 2007 Financial Results 15Mathew to Lead PPD Drug Development Operations and Expansion in India 2Mathew to Lead PPD Drug Development Operations and Expansion in India 3Beckman Coulter Elects AMN Healthcare Executive to Board of Directors 2
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
(Date:11/2/2014)... to put a flashlight up to our palms to ... in St. Louis engineers are using a similar idea ... imaging of cancerous tissues and to develop potential treatments. ... Distinguished Professor of Biomedical Engineering at the School of ... technology that allows researchers to better focus light in ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... KAN. -- It,s a cloak that surpasses all others: ... change the way bacteria and other cells are imaged. ... Kansas State University, and his research team are wrapping ... bacteria under electron microscopes. Berry,s method creates a carbon ...
... 15In the latest twist on optical knots, New York ... create extended and knotted optical traps in three dimensions. ... Optical Society,s (OSA) open-access journal Optics Express , ... intensity traces out a knotted trajectory in space, for ...
... variety of plant seedlings suffer most from competition when planted ... relatives in field soils, researchers from Case Western Reserve University ... when seeds of the same species are buried among relatives ... and grow better early in life in close relatives, habitats ...
Cached Biology News:All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 2All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 3Tying the knot with computer-generated holograms: Winding optical path moves matter 2Tying the knot with computer-generated holograms: Winding optical path moves matter 3Seedlings thrive with distant relatives, seeds with close family 2
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Biology Products: